Beck Bode LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Beck Bode LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,510	Closed	-$1.24M	–	155
2023 Q1	$1.24M	Sell	1,510 -201	-12%	-$152K	0.3%	82
2022 Q4	$1.23M	Buy	1,711 +1,280	+297%	+$944K	0.28%	81
2022 Q3	$297K	Buy	431 +4	+0.9%	+$2.52K	0.06%	150
2022 Q2	$252K	Sell	427 -27	-6%	-$17.6K	0.05%	161
2022 Q1	$317K	Buy	+454	New	+$287K	0.07%	119
2021 Q4	–	Sell	-12,681	Closed	-$7.67M	–	100
2021 Q3	$7.67M	Sell	12,681 -191	-1%	-$119K	2.14%	22
2021 Q2	$7.19M	Buy	12,872 +50	+0.4%	+$25.3K	1.98%	23
2021 Q1	$6.07M	Buy	+12,822	New	+$6.24M	1.87%	24
2020 Q4	–	Sell	-37	Closed	-$21K	–	217
2020 Q3	$21K	Buy	+37	New	+$22.4K	0.01%	166
2020 Q2	–	Sell	-6,132	Closed	-$3.23M	–	54
2020 Q1	$3.23M	Buy	+6,132	New	+$2.53M	1.48%	28

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Beck Bode LLC's REGN Position: Q2 2023 in Review

Beck Bode LLC sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 1,510 shares — an estimated $1.24M sold.

Beck Bode LLC first reported a position in REGN in Q1 2020 and held it in 10 quarters. The position peaked at $7.67M in Q3 2021. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Beck Bode LLC reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Beck Bode LLC sold 1,510 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $1.24M.
Beck Bode LLC first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Beck Bode LLC's Regeneron Pharmaceuticals position peaked at $7.67M in Q3 2021.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Beck Bode LLC's 13F filing for Q2 2023, filed 10 Aug 2023.